Maria Højberg Knudsen1,2, Helle Juhl Simonsen1, Jette Lautrup Battistini Frederiksen2,3, Ulrich Lindberg1, Mark Bitsch Vestergaard1, Henrik Bo Wiberg Larsson1,2, and Stig Præstekjær Cramer1
1Dept. Clinical Physiology, Rigshospitalet, Glostrup, Denmark, 2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 3Dept. of Neurology, Rigshospitalet, Glostrup, Denmark
1Dept. Clinical Physiology, Rigshospitalet, Glostrup, Denmark, 2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 3Dept. of Neurology, Rigshospitalet, Glostrup, Denmark
The
treatment associated change in the patlak derived influx constant in grey
matter of relapsing-remitting multiple sclerosis patients undergoing alemtuzumab
treatment predicted disease activity within two years and may be used as a
biomarker of treatment efficacy.
Change
in grey matter BBB permeability from baseline to six months for subjects with
and without (NEDA) disease activity within two years. Mean difference –0.038 ml/100g/min,
95% confidence interval -0.073;-0.004, p = 0.03.
Change in
grey matter BBB permeability from baseline after treatment as measured by Ki
for subjects with and without (NEDA) disease activity within two years. Dashed
lines = individual trajectories, solid line = group means, error bars = means ± standard error of the mean.